Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01810952 · ClinicalTrials.gov registry record · Phase 4
The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
A Phase 4 study of Diabetes Mellitus and Hyperglycemia, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT01810952 is a Phase 4 study of Diabetes Mellitus and Hyperglycemia that has completed, run by Baylor College of Medicine. The registered enrollment target is 37 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01810952, a Phase 4 study of Diabetes Mellitus and Hyperglycemia, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that includes patient weight and glucocorticoid dose can be used to safely initiate insulin treatment in diabetic/hyperglycemic patients who are to be treated with pharmacological doses of glucocorticoids.
Conditions Studied
Interventions
- DRUG Glargine insulin
- DRUG Lispro insulin
- DRUG NPH Insulin
Study Locations (1)
Texas
- St. Luke's Episcopal Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01810952
The ClinicalTrials.gov registry entry for NCT01810952 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Glargine insulin is the first listed.
NCT01810952 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01810952 about?
NCT01810952 is a clinical study titled "The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients". The investigators hypothesize that includes patient weight and glucocorticoid dose can be used to safely initiate insulin treatment in diabetic/hyperglycemic patients who are to be treated with pharmacological doses of glucocorticoids.
What is the current status of trial NCT01810952?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2010-09. Estimated completion is 2013-09.
What conditions does trial NCT01810952 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Hyperglycemia.
What interventions are being tested in trial NCT01810952?
The interventions under investigation include: Glargine insulin (DRUG), Lispro insulin (DRUG), NPH Insulin (DRUG).
Who is sponsoring clinical trial NCT01810952?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01810952 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Oral Anti Diabetic Agents in the Hospital
ACTIVE NOT RECRUITING · Phase 4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction
COMPLETED · Phase 4
-
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.
COMPLETED · Phase 4
-
A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.